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Introduction
Capnocytophaga canimorsus is a Gram-negative bacterium belonging to the family Flavobacteriaceae in the phylum Bacteroidetes [1] . It is present in the oral flora of dogs [1, 2] , and causes rare but severe dog bite-related bloodstream infections in humans, with a mortality rate as high as 30% [3] (for reviews, see [3] [4] [5] ). C. canimorsus sepsis can be accompanied by bleeding disorders, such as disseminated intravascular coagulation (DIC) (13-35% of all cases), which often results in gangrene (8-13%) . Patients frequently show skin manifestations, including petechiae and purpura (11-46%) [3] [4] [5] [6] . Furthermore, one-third of autopsies performed on deceased individuals reveal hemorrhage of adrenal glands [3] .
The presence of pathogens or their products in the circulation provokes several procoagulant processes, such as tissue factor expression by monocytes and endothelial cells, fostering entrapment of bacteria inside fibrin clots [7] . The importance of coagulation in innate immunity is illustrated by in vivo data. For instance, infection of fibrin-deficient or coumadin-treated mice with Yersinia enterocolitica leads to an elevated pathogen burden and reduced survival [8] . Some bacteria interact with coagulation factors, thus modulating this first step of immune defense [9] [10] [11] . Yersinia pestis, for example, suppresses fibrin generation via the plasminogen activator Pla, thereby reducing recruitment of leukocytes to the infection site [12] .
In view of these facts and the frequent occurrence of bleeding abnormalities during C. canimorsus infection, we investigated the impact of C. canimorsus on hemostasis. We demonstrate that the blood culture isolate C. canimorsus 5 (Cc5) blocks coagulation via the C. canimorsus type 7 dipeptidyl peptidase (CcDPP7), which inactivates coagulation factor X by proteolytic cleavage. We hypothesize that this could contribute to immune evasion of the bacteria and to the hemorrhage observed in patients.
Materials and methods

Bacteria and growth conditions
Bacterial strains are listed in Table S5 . Cc5 was grown on blood agar plates (heart infusion agar [Difco, Franklin Lakes, NJ, USA], 5% defibrinated sheep blood [Oxoid, Basingstoke, UK], and gentamicin). Escherichia coli strains were routinely cultured in LB medium (Invitrogen, Waltham, MA, USA). The concentrations of antibiotics used were as follows: 10 lg mL À1 erythromycin, 10 lg mL À1 cefoxitin, 20 lg mL À1 gentamicin, 50 lg mL À1 kanamycin, 100 lg mL À1 ampicillin, and 35 lg mL À1 nalidixic acid.
Preparation of normal pooled plasma
Human plasma was obtained from 16 healthy volunteers. Blood was drawn into vacutainer tubes (Venosafe; TER-UMO, Tokyo, Japan) containing 0.109 mol L À1 buffered sodium citrate, and centrifuged twice at 2500 9 g for 15 min at room temperature. Normal pooled plasma (NPP) was snap-frozen and stored at À 80°C. The study was approved by the ethics committee of Mont-Godinne, Belgium (Protocol number B039201316262), and performed according to the Declaration of Helsinki and the Belgian law on experiments in humans from 7 March 2004. Participants were informed about the aim of the study and risks of blood withdrawal, and gave written consent.
Calibrated automated thrombogram (CAT) assay
All bacteria were grown on blood agar and incubated with NPP, and cell-free supernatants were added to MPor PPP-Reagent (Thrombinoscope BV, Maastricht, the Netherlands). Control NPP was mixed with a thrombin calibrator (Thrombinoscope BV). 
Generation of knock-out mutants
Primers are listed in Table S6 . Site-directed mutagenesis was performed as described by Mally et al. [13] with primers 1.1 and 1.2 to amplify the upstream flanking region (fragment 1) and primers 2.1 and 2.2 to amplify the downstream flanking region (fragment 2) of the gene to be knocked out. Primers 3.1 and 3.2 were used to amplify the ermF resistance cassette (fragment 3). In contrast to Mally et al., we first fused fragment 1 with fragment 3 in a separate PCR reaction before fusing this to fragment 2.
Construction of complementation and expression plasmids
Plasmids and primers are listed in Tables S7 and S6 , respectively. The dpp7 gene was amplified with primers 7982 and 7983 and inserted into pMM47 [13] , generating the complementation plasmid pKH28. Dpp7 was amplified with primers 7982 and 7989, introducing a C-terminal Strep-His tag, and inserted into pPM5 [14] to generate plasmid pKH32. Plasmids were purified from One Shot TOP10 Electrocomp E. coli (Thermo Scientific), and transformed into Cc5 Ddpp7 bacteria. Positive clones were isolated on cefoxitin blood agar plates. Primers 5451 and 4730 or 7809 and 4730 were used for sequencing of inserts in pMM47 or pPM5, respectively.
Construction of the catalytic CcDPP7 mutant
We introduced a point mutation in the dpp7 gene, replacing the active site serine of CcDPP7 with an alanine (S649A), and added a C-terminal Strep-His tag for purification. Dpp7 was amplified in two fragments by the use of primers 7982 and 7999 or 7998 and 7989, which were then fused with primers 7982 and 7989 (Table S6 ). The product was inserted into pPM5, generating pKH33. We then proceeded as described above.
Protein purification
Cc5 Ddpp7 (pKH32) and Cc5 Ddpp7 (pKH33) bacteria were disrupted with a French press. Cleared lysates were purified with a HisTALON resin (Clontech Laboratories, Mountain View, CA, USA) and a Streptactin resin (Iba), according to the manufacturer's instructions. Purity was assessed by silver staining as described previously [15] (Fig. S1 ).
Immunoblotting
The following primary antibodies were used: rabbit antiserum raised against purified CcDPP7-Strep-His (1 : 5000; this work), mouse mAb HFX-LC and mAb HFX-HC (1 : 1000 and 1 : 1500, respectively; Enzyme Research Laboratories, South Bend, IN, USA), and rabbit anti-F10A cleaved Ala41 (1 : 1000; AssaybioTech, Sunnyvale, CA, USA). The following secondary antibodies were used: swine anti-rabbit horseradish peroxidase (HRP) (1 : 5000; Dako, Santa Clara, CA, USA) and goat anti-mouse HRP (1 : 5000; Dako). Lumiglo Reserve Chemoluminiscent Substrate (KPL, Gaithersburg, MD, USA) was used for development, according to the manufacturer's instructions.
Quantification of CcDPP7 release
One hundred and sixty microliters of supernatants of NPP or heat-inactivated plasma (HIP) treated with 10 9 wild-type (WT) Cc5, with Ddpp7 or with phosphate-buffered saline (PBS) were added to 40 lL of L-methionyl-L-leucyl-4-methylcoumaryl-7-amide (Peptanova, Sandhausen, Germany; final concentration of 250 ng mL À1 ) and incubated for 8 min at 37°C. Fluorescence was read on a Fluoroskan Ascent (excitation/emission: 355 nm/460 nm). A dilution series of a CcDPP7 standard was added for quantification purposes.
N-terminal sequencing
Twenty-five micrograms of FX in PBS was incubated with or without CcDPP7 for 30 min at 37°C. Concentrated samples ) and FII (10 lg mL À1 ) were mixed 1 : 1 with factor-deficient plasma.
Evaluation of tail bleeding time
Balb/c mice were obtained from the University of Namur and Harlan Laboratories (the Netherlands), and housed at the animal facility of the University of Namur. Experiments were performed in accordance with institutional guidelines and animal bioethics consent (approval no. UN LE 13/205). Mice were injected with 200 lL of 1 mg kg À1 CcDPP7 or with 200 lL of the vehicle PBS.
Warfarin was administered for 3 days with the drinking water. After anesthesia with ketamine/Domitor (82.5 mg kg À1 /0.55 mg kg
À1
), a 5-mm-long piece of the tail tip was removed, and the tail was submerged in warm PBS (37°C). The total bleeding time represents all bleeding periods that occurred within 10 min.
Results
Cc5 inhibits thrombin generation
To determine whether C. canimorsus interferes with coagulation, we performed a CAT assay, in which thrombin generation was monitored with a fluorogenic thrombin substrate. We incubated NPP with different amounts of Cc5 bacteria, and induced thrombin generation via the intrinsic pathway (MP-Reagent) or the extrinsic pathway (PPP-Reagent) at different time points. Both pathways were affected at concentrations from 10 7 bacteria mL À1 , and completely blocked at 10 8 bacteria mL À1 . The inhibitory effect already occurred after 15 min ( Fig. 1A ; Table S1 ), and increased slightly when the incubation time was prolonged to 1 h ( Fig. 1B ; Table S2 ). A slight, but insignificant, acceleration of thrombin generation occurred with MP Reagent, which might have resulted from the activation of the intrinsic pathway on the A concentration of 10 9 bacteria mL À1 was used for all conditions, and the incubation was always performed for 1 h at 37°C. One-way-ANOVA with a Bonferroni post hoc test was used for statistical analysis. HC, heavy chain; LC, light chain; NS, not significant. surface of Cc5, as shown for other bacteria [16] . Two other Gram-negative control strains, E. coli MG1655 and Y. enterocolitica E40, did not inhibit thrombin generation, and paraformaldehyde fixed Cc5 only slightly reduced the amount of generated thrombin ( Fig. 1C ; Table S3 ), suggesting that the inhibitory effect was specific to Cc5 and mediated by an active mechanism.
Cc5 prolongs the PT and APTT
We next measured the PT and the APTT of Cc5-treated NPP; these allow the detection of deficiencies in the extrinsic and the common pathway, or in the intrinsic and the common pathway, respectively [17, 18] . As this method is less sensitive than the CAT assay, 10 9 bacteria mL À1 were used and incubated for 1 h. NPP treated with Cc5 showed a 10-fold increased PT (Fig. 1D ) and a two-fold to three-fold increased APTT (Fig. 1E) , thus confirming that Cc5 exerts an inhibitory effect on the coagulation cascade and that all pathways are impaired. When we tested the activity of different coagulation factors, we found that four vitamin K-dependent (VKD) clotting factors were affected. FX and FIX activities were strongly decreased to 1% of normal, and FII and FVII activities by > 50%, hinting at either dysfunction or depletion of these factors by the bacteria (Table 1A) . There was no effect on fibrin(ogen), as confirmed by thrombin time and reptilase time assays, both of which allow the detection of fibrin(ogen) deficiencies (Table 1B) .
FX is cleaved by a bacterial serine protease
We investigated the fate of FX, one of the most affected VKD factors. When we incubated Cc5 bacteria with NPP spiked with radiolabeled FX, we observed protein modifications, with a slight band shift of the FX heavy chain (HC) and light chain (LC). These no longer occurred upon prior treatment of the bacteria with the irreversible serine protease inhibitor AEBSF ( Fig. 2A) , suggesting cleavage by a bacterial serine protease. In addition, there was Cc5-mediated generation of two faint bands below the HC, which were still visible after AEBSF treatment of the bacteria, indicating that another bacterial factor, potentially another protease or a deglycosylase, also affected FX. As preincubation of Cc5 with AEBSF completely abolished the increased clotting times (Fig. 2B) , serine protease-mediated FX LC and HC degradation seems to be the main cause of the increase in the APTT and PT, and will be the focus of this article.
Identification of the bacterial serine protease affecting FX activity
According to the MEROPS protease database, the Cc5 genome [19] encodes 27 potential serine proteases (Table S4) , which we individually deleted by gene-directed mutagenesis. All mutants behaved like WT bacteria (data not shown), except for one, DCcan_08540, which no longer led to an increased PT (Fig. 3A) . There was still a small increase in the APTT (Fig. 3B) , which might have resulted from the hypothetical second factor modifying the FX HC or from an interaction of Cc5 with molecules in the APTT reagent. The normalization of the PT and APTT in DCcan_08540 bacteria-treated NPP coincided with intact FX function (Fig. 3C ) and the disappearance of the HC and LC band shift of FX (Fig. 3D) . A complemented strain of DCcan_08540, DCcan_08540 (pKH28), behaved similarly to WT Cc5, meaning that the mutation of Ccan_08540 was indeed responsible for the phenotype (Fig. 3A-C) . These findings indicate that Ccan_08540 encodes a serine protease that is responsible for FX cleavage and inhibition of coagulation.
Ccan_08540 encodes a DPP7 homolog
In MEROPS, the protein encoded by Ccan_08540 is annotated as a dipeptidyl peptidase 11 (DPP11)-like protease, a member of the S46 family of serine proteases. When we aligned the amino acid sequence of the Ccan_08540 protease with that of the DPP11 homolog of Porphyromonas gingivalis (PgDPP11) [20] (Fig. S2) , we found that Ccan_08540 has a glycine instead of an arginine at P667. As this arginine is a hallmark of DPP11 proteases [21] , its substitution by a glycine, as in PgDPP7, another P. gingivalis dipeptidyl peptidase, indicates that Ccan_08540 is, rather, a member of the DPP7 subgroup of S46 proteases [21] . We therefore called it CcDPP7. The Ccan_08540 gene, which we named dpp7, could be identified in all 26 C. canimorsus strains that we have sequenced so far, with a gene identity of > 99% (Fig. S3A) . Cc5 also possesses a DPP11 homolog, which is encoded by Ccan_11580, but it is not implicated in the anticoagulant effect (data not shown).
CcDPP7 homologs are present in the genomes of other Capnocytophaga species, such as Capnocytophaga cynodegmi and Capnocytophaga canis, that cause wound infections, but no sepsis (Fig. S3A) [1, 22] . Twelve further C. canimorsus and three C. canis strains that we tested increased the PT and APTT in a similar manner. Three tested C. cynodegmi strains were less efficient in affecting the PT, but prolonged the APTT like C. canimorsus (Fig. S3B) .
CcDPP7 is released into plasma via bacterial lysis
Being devoid of a signal peptide, CcDPP7 is likely to be cytoplasmic. As the Cc5 genome contains no evidence of machinery allowing active secretion, except for the gliding motility system [19] , and as C. canimorsus is killed by complement at high plasma concentrations [23] , we speculated that complement-mediated lysis could induce CcDPP7 release. When we incubated 10 9 bacteria mL À1 in NPP, we observed that 60% of the bacteria had died within 15 min (Fig. 4A) . No more killing occurred up to 1 h. When complement was inactivated by heat treatment of plasma, there was no killing and even slight growth. Using a fluorogenic dipeptide substrate cleaved by CcDPP7, we observed a strong time-dependent increase of fluorescence in the supernatants of NPP, but not in HIP, incubated with WT Cc5 bacteria (Fig. 4B) , suggesting the liberation of CcDPP7 by bacterial lysis. In the same conditions, Ddpp7 bacteria resulted in low fluorescence, confirming that substrate cleavage was mainly caused by CcDPP7. Using serial dilutions of purified CcDPP7 (Fig. S1 ), we calculated that 10 9 WT Cc5 mL
À1
of NPP release an average of 942 ng of CcDPP7 (Fig. 4C ). This might be a slight overestimation, given the low activity of other Cc5 proteases on the substrate. However, if we assume 60% lysis (Fig. 4A) , the value is in the same range as that obtained by a quantitative western blot assay, which showed that 10 9 bacteria contain, on average, 1.49 lg of CcDPP7 (Fig. 4D) . To conclude, CcDPP7 is rapidly released into plasma via bacterial lysis.
CcDPP7 cleaves the N-termini of FX LC and HC
We next characterized the cleavage of FX by purified CcDPP7. We first confirmed the anticoagulant action of the purified protease. Indeed, NPP incubated with CcDPP7 showed dose-dependent increases in PT and APTT (Fig. 5A) , reduced VKD factor activity (Fig. 5B) , and an altered molecular weight of FX (Fig. 5C,D) . A catalytic mutant of CcDPP7, CcDPP7 S649A , in which the active serine had been replaced by an alanine, was inactive. To test the efficiency of CcDPP7 in cleaving FX, we performed a PT assay with FX-deficient plasma, which we supplemented with FX that was pretreated with CcDPP7 at different concentrations. We observed a significant increase in the PT starting from an enzyme/substrate ratio of 1 : 50 (by weight) as compared with the control (Fig. 6A) , which corresponds to the ratio needed to significantly increase the PT in NPP (Fig. 5A) , assuming a plasma FX concentration of 10 lg mL
À1
. The PT maximum was reached at ratios of 1 : 10 to 1 : 4. To exclude any interference of CcDPP7 with FX-deficient plasma at the moment of induction, we added a control, incubating FX and CcDPP7 separately and only mixing them upon addition to FX-deficient plasma when clotting was induced. The PT was normal in this condition, meaning that the effect was only triggered by the interaction of CcDPP7 with FX.
We additionally monitored FX degradation by SDS-PAGE followed by silver staining, and found that a CcDPP7/FX ratio of 1 : 1000 was already sufficient to at the indicated enzyme/substrate ratios (by weight), and subsequently added to FX-deficient plasma at a concentration of 10 lg mL À1 . To exclude any interaction of CcDPP7 with FX-deficient plasma at the moment of induction, a control was included for which FX and CcDPP7 were first incubated separately and only mixed upon addition to FX-deficient plasma when the inducer was added (n.c., no coincubation). Mean values and standard deviations of three independent experiments, each performed in triplicate, are shown. **P ≤ 0.01, ***P ≤ 0.001 versus control. One-way-ANOVA with a Bonferroni post hoc test was used for statistical analysis. (B) Degradation of pure human FX by CcDPP7 happens in a dose-dependent manner, but reaches a limit at high doses. FX (50 lg mL À1 ) in phosphate-buffered saline (PBS) was incubated with CcDPP7 at the indicated ratios (by weight) for 30 min at 37°C. Ten microliters of each sample in sample buffer was loaded. Representative silver staining of three independent experiments is shown. initiate a clearly visible band shift of the FX HC (Fig. 6B) . The LC shift was more obvious from 1 : 250, indicating that CcDPP7 could have a higher specificity for the HC.
The discrepancy between this test and the PT assay may result from the high sensitivity of the silver staining, which detected partial degradation, and the low sensitivity of the neoplastin reagent, which contains high amounts of TF. The DPP7 homolog of P. gingivalis is an aminopeptidase [24] . To explore whether CcDPP7 degrades the FX N-terminus, we incubated FX with CcDPP7 at different ratios, and analyzed the FX LC by western blotting with an antibody recognizing the first 20 amino acids. There was reduced antibody binding from a 1 : 250 ratio, indicating N-terminal cleavage (Fig. 6C) . CcDPP7 S649A did not induce N-terminal cleavage of the LC (Fig. S4) . N-terminal sequencing was performed to confirm this result and to investigate the fate of the HC. Because, at a ratio of 1 : 4, no more binding of the LC antibody occurred and the FX HC and LC were shifted to a maximum, suggesting that all FX molecules had been cleaved (Fig. 6B) , we decided to use this condition for sequencing. We found that, mainly, 10 N-terminal amino acids of the HC and two amino acids of the LC were missing (Fig. 6D) , confirming the aminopeptidase nature of CcDPP7.
Apart from FX, CcDPP7 also acted on FIX (Figs 5B and S5C) and FVII, but the latter action was weaker and less specific (Figs 5B and S5B). It is likely that the N-termini of FIX and FVII undergo limited cleavage, but, so far, we have no evidence for this. CcDPP7 reduced FII activity in NPP (Fig. 5B ), but did not reduce the activity of purified FII (Fig. S5A) . This raises the question of whether the impact of CcDPP7 on FII observed in NPP was overestimated, owing to an effect on multiple coagulation factors, or whether our assay with purified FII was not sensitive enough.
CcDPP7 is active in vivo
In order to confirm the anticoagulant activity of CcDPP7 in vivo, we administered the enzyme to Balb/c mice by intravenous injection. One hour after CcDPP7 administration, the median tail bleeding time was two-fold higher than in the control (Fig. 7) . Mice of the positive control group, which had received warfarin, showed a three-fold increase in the median tail bleeding time as compared with the mock-treated control group.
Discussion
Although coagulation disorders classically accompany generalized infections, the bleeding and coagulation abnormalities are particularly severe in the case of C. canimorsus infection, often leading to therapeutic amputations [25] [26] [27] [28] [29] . When we investigated the possible interaction between C. canimorsus and hemostasis, we found that Cc5 inhibited coagulation of human plasma via a bacterial serine protease of the DPP7 type (CcDPP7), which caused cleavage of the N-termini of the FX LC and HC. Removal of all but three amino acids of the FX activation peptide hampers the activation by the intrinsic FXase [30] . The HC cleaved by CcDPP7 lacks only 10 amino acids, but this could be sufficient to decrease the rate of FX activation. CcDPP7 predominantly cleaves two amino acids from the N-terminus of the LC, which comprises a c-carboxyglutamic acid (Gla) domain. Even the absence of the very first alanine (A1) can affect FX activity by preventing the formation of hydrogen bonds with Gla16, Gla20, Thr21, and Gla21, which normally mediate conformational stability of the Gla domain [31] . In addition, A1 contributes to the generation of a Ω-loop, which stretches until Gly11 [31] and is necessary for the interaction of the Gla domain with membrane surfaces [32] . This suggests that, although CcDPP7 cleaves only a few residues from the FX HC and LC N-termini, it could be sufficient for FX inactivation. It would be of great interest to identify the mechanism of interaction of CcDPP7 with FX, which should help to clarify its preference for certain factors, and to investigate why CcDPP7 stops cleaving after a limited number of amino acids from the HC and LC. Even with very high enzyme concentrations, no further cleavage occurs (Fig. 6B) . A possible cause could be post-translational modifications causing steric hindrance, such as glycans, or a complex secondary structure making further amino acids less accessible.
Owing to its intracellular location, CcDPP7 might essentially be a housekeeping protease that could nevertheless play a role in cleaving clotting factors in plasma, because it is strongly released by the complementmediated lysis of Cc5 bacteria. As CcDPP7 is also expressed by strains not causing invasive infections, it is clear that the possession of CcDPP7 alone does not suffice to make C. canimorsus a pathogenic bacterium. Other factors, such as the weakly endotoxic lipopolysaccharide [33] , the resistance to phagocytosis [34] , the capacity to capture iron [14] , and the N-glycoprotein deglycosylation [35] , cooperate to determine pathogenicity. Unfortunately, the investigation of virulence factors has been hampered by the lack of animal models permitting the investigation of pathogenesis in vivo. Rabbits [36] , mice and hamsters (unpublished data) clear bacteria completely. In vitro, in human plasma, CcDPP7 was effective in the nanogram range, and 10 7 bacteria mL À1 sufficed to affect thrombin generation. In the mouse,~17 lg of pure CcDPP7 mL À1 blood was required to increase the tail bleeding time. We have no obvious explanation for this discrepancy, but protein stability, the presence of inhibitors or other unknown targets in murine blood could play a role. Some clinical reports mention the presence of extracellular bacteria in peripheral blood smears [37, 38] , indicating a high bacterial load. However, in most cases, C. canimorsus was only detected by culture, suggesting lower bacterial numbers. This raises the question of whether CcDPP7 could have systemic activity.
A generalized anticoagulant effect would probably only occur at advanced stages of sepsis, when bacteremia is high and many bacteria have lysed, releasing their intracellular contents. CcDPP7 levels are probably not sufficient to prevent DIC; there could be, at most, aggravation of DIC-induced hemorrhage.
C. canimorsus adheres to various cell types, including endothelial cells (unpublished data), and vegetations have been found within the heart [39] . Local inhibition of coagulation by agglomerates of adhering bacteria in tissues, organs or blood vessels releasing CcDPP7 seems to be more probable. Brenner et al. mentioned a C. canimorsus isolate derived from a petechial lesion [1] , pointing to the presence of C. canimorsus in the skin, which is interesting with respect to the skin hemorrhage observed in patients. It is tempting to speculate that C. canimorsus could directly induce skin manifestations, like Neisseria meningitidis [40, 41] , or that it could reduce the inflammatory response and clearance, like Y. pestis [12] , by locally blocking hemostasis.
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